Fig. 5. CAP-Mac is more potent in human cultured neurons compared with AAV9.
a, Differentiation process starting with an iPSC line that was differentiated into neural progenitor cells, which were further differentiated into mature neurons. b, Representative images of cultured human neurons after 4 days of incubation with either CAP-Mac (top) or AAV9 (bottom) packaging ssCAG-eGFP across four doses of AAV, ranging from 101 to 105 vg per cell. c,d, Dose response curves of AAV9 (n = 3 biologically independent replicates) and CAP-Mac (n = 3 biologically independent replicates) in mature human neuron cultures measuring the transduction efficiency (c) and mean eGFP intensity (d). Mean values ± s.e.m. are shown.